Therapeutic area
Neuro
Neurodegeneration, psychiatry, pain, and CNS platforms, from the grant that funded the target to the first trial.
6,097 pre-ticker companies classified in neuro right now.
Pipeline by stage
Where these companies sit on the ladder from a first grant to an approved product. Derived from evidence in public filings, never inferred past it.
- Grant-only5,648
- Formed18
- Preclinical0
- IND-enabling0
- Phase I100
- Phase II165
- Phase III110
- Filed/Approved56
Highest momentum in neuro
Not included in your seat
Neuro is outside your seat
The counts above are public. The ranked companies, their momentum, and their dossiers in Neuro follow your seat. The free tier covers oncology; a Fund or Feed seat covers every area, and an Analyst seat can be switched to neuro from your account.
Counts are public federal records; momentum is a recency-weighted score over public filing events, shown identically to every viewer. Informational only, not investment advice. All areas · Methodology